News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Achillion Pharmaceuticals, Inc. Provides Update on Clinical HCV Development Programs
November 12, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW HAVEN, Conn., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today provided an update on the sovaprevir and ACH-3102 clinical development programs and announced new Phase 1b clinical trial results on ACH-2684.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Phase 2
MORE ON THIS TOPIC
Insights
HER2’s Digital Rebirth Is Unlocking the Full Potential of ADCs
February 10, 2026
·
3 min read
·
Jennifer Smith-Parker
Gene therapy
Liver Toxicities Force Pause on Two Dose Groups of UniQure’s Mid-Stage Fabry Study
February 9, 2026
·
1 min read
·
Tristan Manalac
Gene therapy
Ultragenyx’s Gene Therapy Shows Long-Term Efficacy in Two Sanfilippo Studies
February 9, 2026
·
2 min read
·
Tristan Manalac
Psychedelics
AbbVie CSO Touts ‘Breakthrough Type Therapy’ Psychedelic as J&J’s Spravato Keeps Growing
February 6, 2026
·
2 min read
·
Dan Samorodnitsky
